Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland ; volume:13 ; number:1 ; day:28 ; month:9 ; year:2022 ; pages:1-10 ; date:12.2022
Nature Communications ; 13, Heft 1 (28.9.2022), 1-10, 12.2022
- Creator
-
Norddahl, Gudmundur L.
Melsted, Pall
Gunnarsdottir, Kristbjorg
Halldorsson, Gisli H.
Olafsdottir, Thorunn A.
Gylfason, Arnaldur
Kristjansson, Mar
Magnusson, Olafur T.
Sulem, Patrick
Gudbjartsson, Daniel F.
Thorsteinsdottir, Unnur
Jonsdottir, Ingileif
Stefansson, Kari
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-022-33076-4
- URN
-
urn:nbn:de:101:1-2022121621040380811715
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Norddahl, Gudmundur L.
- Melsted, Pall
- Gunnarsdottir, Kristbjorg
- Halldorsson, Gisli H.
- Olafsdottir, Thorunn A.
- Gylfason, Arnaldur
- Kristjansson, Mar
- Magnusson, Olafur T.
- Sulem, Patrick
- Gudbjartsson, Daniel F.
- Thorsteinsdottir, Unnur
- Jonsdottir, Ingileif
- Stefansson, Kari
- SpringerLink (Online service)
Other Objects (12)
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Clinical characteristics and booster vaccine effectiveness of the Omicron variant